摘要
目的:研究尼可胺的致突变性,为临床安全用药提供理论依据。方法:采用Ames试验、小鼠微核试验及中国仓鼠肺细胞(CHL)染色体畸变试验检测尼可胺的致突变性。结果:Ames试验中在加和不加代谢活化系统(S9)的条件下,尼可胺各剂量组(每皿8、40、200、1000、5000μg)4种实验菌株的平均回变菌落数均在相应菌株自发回变数的2倍以内,且无剂量-反应关系。尼可胺各剂量组(400、200、100mg/kg)小鼠骨髓细胞微核率及CHL细胞染色体畸变率与阴性对照组比较,其差异均无统计学意义(P>0.05)。结论:在本实验条件下,尼可胺无致突变作用。
OBJECTIVE：To study the genetic toxicity of NiKeAn.METHODS：the mutagenicity of NiKeAn was examined using Ames test,micronucleus test and CHL cell chromosome aberration test.RESULTS：No increase in the number of revertant colonies was found in the Ames test with and without S9 mixture.The micronucleus rates and chromosome aberration rates at all doses were not significantly different from the control group（P0.05）. CONCLUSION：Mutagenicity of NiKeAn was not observed in this study.
出处
《癌变．畸变．突变》
CAS
CSCD
2011年第5期392-394,共3页
Carcinogenesis,Teratogenesis & Mutagenesis
基金
天津市科技支撑计划重点项目(09ZCKFSH01500)
